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Abstract: Ketamine and its primary metabolite norketamine attenuate morphine tolerance by antagonising N-methyl-D-aspartate
(NMDA) receptors. Ketamine is extensively metabolized to several other metabolites. The major secondary metabolite
(2S,6S;2R,6R)-hydroxynorketamine (6-hydroxynorketamine) is not an NMDA antagonist. However, it may modulate nociception
through negative allosteric modulation of a7 nicotinic acetylcholine receptors. We studied whether 6-hydroxynorketamine could
affect nociception or the effects of morphine in acute or chronic administration settings. Male Sprague Dawley rats received sub-
cutaneous 6-hydroxynorketamine or ketamine alone or in combination with morphine, as a cotreatment during induction of mor-
phine tolerance, and after the development of tolerance induced by subcutaneous minipumps administering 9.6 mg morphine
daily. Tail flick, hot plate, paw pressure and rotarod tests were used. Brain and serum drug concentrations were quantified with
high-performance liquid chromatography–tandem mass spectrometry. Ketamine (10 mg/kg), but not 6-hydroxynorketamine (10
and 30 mg/kg), enhanced antinociception and decreased rotarod performance following acute administration either alone or com-
bined with morphine. Ketamine efficiently attenuated morphine tolerance. Acutely administered 6-hydroxynorketamine increased
the brain concentration of morphine (by 60%), and brain and serum concentrations of 6-hydroxynorketamine were doubled by
morphine pre-treatment. This pharmacokinetic interaction did not, however, lead to altered morphine tolerance. Co-administration
of 6-hydroxynorketamine 20 mg/kg twice daily did not influence development of morphine tolerance. Even though morphine
and 6-hydroxynorketamine brain concentrations were increased after co-administration, the pharmacokinetic interaction had no
effect on acute morphine nociception or tolerance. These results indicate that 6-hydroxynorketamine does not have antinocicep-
tive properties or attenuate opioid tolerance in a similar way as ketamine.
Opioids are widely used to manage severe acute and cancer
pain. However, prolonged opioid use in chronic non-cancer
pain may have severe drawbacks, including the development
of tolerance and dependence. In the United States, eighty per
cent of new heroin users have previously misused prescription
opioids, and the opioid epidemic has been declared a national
emergency [1]. Long-term opioid use may even lead to opi-
oid-induced hyperalgesia that can compromise opioid analge-
sia and lead to further increases in opioid doses [2]. New
approaches are needed to provide safer opioid analgesia with
lower doses.
Several N-methyl-D-aspartate (NMDA) receptor antagonists
have been shown to attenuate opioid tolerance [3–5] mainly
via pharmacodynamic interactions. Ketamine, a clinically used
NMDA antagonist, produces anaesthesia and also analgesia at
lower doses. Clinical evidence supports the perioperative use
of low-dose ketamine with morphine to decrease the need for
morphine [6], whereas there is lack of evidence to support its
use in cancer pain as an adjunct with opioids [7,8].
Ketamine undergoes extensive cytochrome P (CYP)-
mediated metabolism to norketamine, hydroxyketamines,
dehydronorketamine and hydroxynorketamines [9,10]. The
best characterized metabolite is the main metabolite norke-
tamine, a three to five times weaker NMDA receptor antago-
nist than ketamine [11–14]. In pre-clinical models, it caused
anaesthesia [12], and at lower doses, augmented the effects of
morphine in models of thermal, peripheral neuropathic and
tonic inflammatory pain [15]. It also inhibited [15] and
reversed [16] morphine tolerance. The effects of administering
norketamine have not been studied in human beings.
After (R,S)-ketamine administration, (2S,6S;2R,6R)-hydro-
xynorketamine (6-hydroxynorketamine) is the most abundant
hydroxynorketamine found in the plasma and brain of mice
[17] and plasma of human beings [18]. It is formed via meta-
bolism from norketamine or hydroxyketamine [19,20]. Its
pharmacological properties have been only scarcely studied
because initial experiments showed that (R,S)-ketamine and
(R,S)-norketamine produced anaesthesia and increased sponta-
neous locomotor activity during recovery from anaesthesia,
whereas 6-hydroxynorketamine had no effects. Therefore, it
was considered an inactive metabolite. However, recent stud-
ies have shown that 6-hydroxynorketamine is pharmacologi-
cally active and it may be responsible for the antidepressant
effects of ketamine [17].
The beneficial interaction between ketamine or norketamine
and opioids has been considered to derive from pharmacody-
namic interactions. However, we have recently reported a phar-
macokinetic interaction between both morphine and ketamine
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[21] and morphine and norketamine [16] in the rat. A single
dose of ketamine or norketamine administered to rats receiving
chronic morphine treatment via subcutaneous pumps caused a
manifold increase in the brain and serum concentrations of mor-
phine, an effect due to the inhibition of hepatic UDP-glucurono-
syl transferase (UGT)-mediated metabolism of morphine. This
finding is supported by previous in vitro studies [22,23]. Fur-
thermore, by an unknown mechanism, chronic morphine treat-
ment led to increased ketamine and norketamine brain and
serum concentrations after acute administration. Thus, the bene-
ficial effects of ketamine and norketamine in attenuating mor-
phine tolerance may in part be due to a pharmacokinetic
interaction. At present, there are no data on the possible pharma-
cokinetic interactions between opioids and other ketamine
metabolites such as 6-hydroxynorketamine.
We hypothesized that 6-hydroxynorketamine may have
effects on nociception through either pharmacokinetic or phar-
macodynamic interactions. We characterized the effects of
6-hydroxynorketamine on nociception and motor coordination
when it was administered alone or combined with morphine in
acute and chronic administration settings. Serum and brain
drug concentrations were quantified to detect possible pharma-
cokinetic interactions.
Methods
Animals. Animal care and research procedures were conducted and
reported in accordance with the guidelines of The International
Association for the Study of Pain [24] and the ARRIVE guidelines
[25,26]. The study protocol was approved by the provincial
government of Southern Finland (Etel€a-Suomen aluehallintovirasto,
H€ameenlinna, Finland, ESAVI/7929/04.10.07/2014). Male Sprague
Dawley rats (Harlan, Horst, the Netherlands, n = 4–7 per study group;
weight 200–250 g) were housed in standard light- and temperature-
controlled rooms (lights on 06:00–18:00 hr, temperature 22  2°C) in
groups of two in individually ventilated plastic cages. Tap water and
standard laboratory chow were available ad libitum. All experiments
were conducted during the light phase. The animals were habituated
to the testing environment for 3 days before the experiments. All
behavioural testings were randomized and blinded. The stress and
suffering of the experimental animals were minimized, and the
animals could freely terminate the noxious stimulation during the
tests. After the experiments, the animals were killed by decapitation
and tissue samples were collected. A total of 70 rats were used in the
experiments.
Drugs for acute nociceptive tests. Morphine hydrochloride and
racemic ketamine hydrochloride (Ketaminol vet, 50 mg/ml,
Boxmeer, the Netherlands) were purchased from the University
Pharmacy, Helsinki, Finland. (2S,6S;2R,6R)-hydroxynorketamine
hydrochloride (6-hydroxynorketamine) was purchased from Tocris
(Bristol, UK). Morphine and 6-hydroxynorketamine were dissolved,
and ketamine was diluted in physiological saline and administered
subcutaneously in a volume of 2 ml/kg. All drug concentrations are
expressed as free base amounts.
Opioid tolerance scheme. Opioid tolerance was induced during
6 days with continuous opioid administration using osmotic
minipumps (Alzet 2ML1; Durect, Cupertino, CA, USA). The pumps
were filled with 40 mg/ml morphine diluted in sterile water to deliver
morphine 9.6 mg/day. For the control animals, sterile water was used
as a vehicle. The pumps were implanted subcutaneously in the back
of the rats under isoflurane (3.0%) anaesthesia.
Behavioural tests. Tail flick, hot plate and paw pressure tests were
used to study heat and mechanical nociception. The rotarod test was
used to assess motor coordination. The baseline latencies for each
experiment day were measured separately immediately before the
administration of any drugs.
Tail flick latencies were measured with a Ugo Basile 37360 (Come-
rio, Italy) radiant heat tail flick device. The rats were restrained in
hard plastic tubes covered with a dark cloth. After acclimatization, the
light was directed to the middle tail at three different points 0.5 cm
apart, and the mean of these three values was used as the result.
A flick of the tail was considered as thermal nociception terminating
the test. If an individual measurement reached cut-off (10 sec.), no
further tests were performed at that time-point. The intensity of the
device was adjusted to produce a baseline latency of approximately
4 sec.
Hot plate tests were performed with a Ugo Basile 35100 hot/cold
plate device. The rats were put into a circular transparent plastic cage
on the hot plate (52  0.2°C). The latency to the first thermal noci-
ceptive reaction, such as licking or shaking of the hind paw or jump-
ing, was measured. A cut-off time of 60 sec. was used.
Paw pressure tests were performed with a Ugo Basile 37215 device.
In the test, animals were gently wrapped in a towel and the left hind
paw of the rat was placed under a pivot. The force applied to the paw
was gradually increased up to a cut-off of 500 g. A brisk withdrawal
of the paw or vocalization terminated the measurement. The test was
performed twice at each time-point with a 1-min interval, and the
mean of these two tests was used as the result.
Rotarod tests were performed with a Ugo Basile 47700 rat rotarod
apparatus, diameter 70 mm, with the speed accelerating from 10 to 40
r.p.m. during the course of 60 sec. The rat was placed on the rotating
rod, and the time it stayed on it was measured, with a cut-off time of
60 sec.
At each time-point, the tests were performed in the same order. The
tail flick test was performed first and the hot plate test second, fol-
lowed by the paw pressure test after a pause of 1 min. The rotarod
test was performed last.
Determination of drug and metabolite concentrations. For
concentration measurements, the rats were decapitated and whole
brain and blood samples were collected. Brain samples were covered
in aluminium foil and snap-frozen in liquid nitrogen, after which they
were stored at 80°C. The blood samples were let to coagulate on ice
after which they were centrifuged at 2000 9 g for 10 min. at +4°C.
Serum was collected and stored at 80°C. For concentration
measurements, the whole brain samples were weighed, homogenized
and diluted in sterile water. Brain tissue samples from untreated rats
were individually spiked with the studied compounds and used as a
standard. The measurements were carried out as previously described
[27] with some modifications using an Agilent 1100 series HPLC
system (Agilent Technologies, Waldbronn, Germany) coupled to an
API 3000 tandem mass spectrometry (AB Sciex, Toronto, ON,
Canada), and the chosen method was validated also for the analysis of
ketamine, norketamine and 6-hydroxynorketamine (data not shown).
The chromatographic separation of morphine, morphine-3-glucuronide
(M3G), ketamine, norketamine and 6-hydroxynorketamine was
achieved on Atlantis HILIC Silica column (3 lm particle size,
2.1 9 100 mm I.D.) (Waters, Milford, MA, USA) using a gradient
elution of mobile phase consisting of acetonitrile and 20-mmol/l
ammonium acetate (pH 3.0, adjusted with formic acid). An aliquot
(5 ll) was injected at a flow rate of 200 ll/min to give a total
chromatographic run time of 24 min. Oxycodone-d3 (Cerilliant,
Round Rock, TX, USA) served as an internal standard for morphine
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and M3G, and 6-hydroxynorketamine served as its own internal
standard. Deuterium-labelled internal standards (ketamine-d4 and
norketamine-d4; Cerilliant) were used for ketamine and norketamine.
The target ion transitions monitored were as follows: morphine m/z
286–152, M3G m/z 462–286, ketamine m/z 238–125, norketamine m/
z 224–125 and 6-hydroxynorketamine m/z 240–141. The limit of
quantification for morphine, M3G and 6-hydroxynorketamine was
1.0 ng/ml in serum and 5.0 ng/g in brain, and 0.5 ng/ml for ketamine
and norketamine in serum and 2.5 ng/g in brain. The calibration
curves were linear over the concentration range of LOQ–250 ng/ml,
and day-to-day coefficients of variation were below 15% at relevant
concentrations for all analytes. None of the measured compounds
interfered with the mass spectrometric assay.
Effects of 6-hydroxynorketamine on nociception and motor
coordination alone and in co-administration with morphine. The
effects of subcutaneous 6-hydroxynorketamine on nociception and
motor coordination were studied alone at two doses (10 and 30 mg/
kg). These doses were selected because in a previous study [17], the
dose of 10 mg/kg showed significant antidepressant effects in a mouse
model. After a week of washout, the effects of 6-hydroxynorketamine
on morphine antinociception were studied using the same animals.
Subcutaneous morphine (2.5 mg/kg) was administered 15 min. before
6-hydroxynorketamine (10 or 30 mg/kg). Tail flick, hot plate, paw
pressure and rotarod tests were performed for up to 90 min. after 6-
hydroxynorketamine administration, with an additional rotarod
measurement at 10 min. In all studies, subcutaneous ketamine (10 mg/
kg) was used as a positive control drug.
Effects of acute 6-hydroxynorketamine in rats under chronic morphine
administration. We investigated the ability of 6-hydroxynorketamine
to reverse the established morphine tolerance. On day 0, rats received
either morphine or vehicle pumps. Development of antinociceptive
tolerance was confirmed on day 6, after which subcutaneous 6-
hydroxynorketamine (10 or 30 mg/kg) was administered. Ketamine
10 mg/kg was used as a positive control. Nociception was monitored
at 30-min. intervals using the tail flick, hot plate and paw pressure
tests. Rotarod performance was measured additionally also at 10 min.
after acute drug administration. After the behavioural tests at 90 min.,
rats were decapitated and tissues were gathered for drug concentration
measurements.
Effects of 6-hydroxynorketamine in developing morphine
tolerance. This experiment assessed the possible effects of 6-
hydroxynorketamine in the development of morphine antinociceptive
tolerance. Before the implantation of morphine minipumps, rats were
given either subcutaneous 6-hydroxynorketamine (20 mg/kg) or
vehicle. This treatment continued twice daily until the end of day 5.
The nociceptive behaviour of the rats was monitored before the
administration of any drugs (day 0) and in the morning of days 2, 4
and 6. The measurements were performed before the administration
of the morning 6-hydroxynorketamine dose. On day 6, a single dose
of subcutaneous morphine (10 mg/kg) was administered to both
groups and the effects were monitored at 30 and 90 min. after
administration. Finally, rats were decapitated and tissue samples
collected.
Statistical analysis. The data and statistical analysis comply with the
recommendations on experimental design and analysis in
pharmacology [28] with minor exceptions. All experiments were
performed blinded, but the data analysis was performed unblinded. In
some data points (concentration analyses), the number of samples per
group was four. However, all nociceptive behavioural experiments
had six to seven animals in the group. The results of the tail flick,
hot plate and paw pressure tests are expressed as percentage of the
maximum possible effect (MPE%), calculated as MPE% = [(postdrug
latency – baseline latency)/(cut-off time – baseline latency)] 9 100%,
which takes into account the differences in baseline nociceptive
latencies. The results are presented as means of the groups
(S.E.M.). The behavioural data were tested for statistically
significant differences in the mean values by two-way analysis of
variance (ANOVA), and a Holm–Sidak post hoc analysis was
performed. For the concentration data, an unpaired two-tailed t-test or
one-way ANOVA followed by the Holm–Sidak post hoc analysis was
used. For the nonparametric rotarod test data, the Kruskal–Wallis test
followed by Dunn’s multiple comparison was used. The difference
was considered significant at p < 0.05 in both the analysis of
variance and the post hoc test. The data were analysed using
GRAPHPAD PRISM, version 6.0e, for Mac OS X (GraphPad Software,
La Jolla, CA, USA).
Results
6-hydroxynorketamine does not possess antinociceptive
properties in acute thermal or mechanical pain.
Compared with vehicle, acutely administered subcutaneous
ketamine (10 mg/kg) caused small but significant antinocicep-
tion in the tail flick (fig. 1A) and paw pressure (fig. 1C) tests
but not in the hot plate test (fig. 1B). Ketamine also signifi-
cantly impaired motor coordination in the rotarod test at
10 min. after administration (fig. 1D). The administered doses
of 6-hydroxynorketamine (10 and 30 mg/kg) did not have
effects on antinociception or motor coordination at any time-
point.
Ketamine but not 6-hydroxynorketamine augments acute
morphine antinociception.
Rats received subcutaneous morphine (2.5 mg/kg) and 15 min.
later subcutaneous ketamine (10 mg/kg) or 6-hydroxynorketa-
mine at two doses (10 and 30 mg/kg). Morphine antinocicep-
tion was at its greatest at 45 min. after administration, and
ketamine significantly augmented the effect of morphine in all
the nociceptive tests (fig. 2A–C). The motor coordination of
rats that received ketamine and morphine was significantly
compromised 10 min. after ketamine administration. Co-admin-
istration of 6-hydroxynorketamine did not significantly augment
morphine antinociception or decrease motor coordination.
Development of morphine tolerance under 6 treatment days.
Morphine pumps were implanted on day 0. Robust antinoci-
ception was detected one day after the procedure in all the
nociceptive tests (fig. 3A–C). On day 6, tolerance to the
antinociceptive effect of morphine was fully developed.
Attenuation of morphine tolerance by ketamine, but not
6-hydroxynorketamine.
Upon the confirmation of the development of morphine toler-
ance on day 6, rats received acute subcutaneous ketamine
(10 mg/kg) or 6-hydroxynorketamine (10 or 30 mg/kg). In the
tail flick test (fig. 4A), ketamine reversed morphine tolerance
from 60 min. after administration to the end of the measure-
ment period (90 min.). Ketamine induced significant reversal
of tolerance also in the hot plate test (fig. 4B) and paw
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pressure test (fig. 4C) at 30 and 60 min. after administration.
Administration of 6-hydroxynorketamine did not lead to atten-
uation of morphine tolerance during the 90-min. measurement
period.
At 90 min., after ketamine or 6-hydroxynorketamine admin-
istration, serum and brain samples were obtained. Acutely
administered 6-hydroxynorketamine (30 mg/kg) significantly
increased (60%) the morphine brain concentration (fig. 4D).
The difference in serum concentrations was parallel but did
not reach significance. The serum M3G:morphine metabolic
ratios were 7.9  1.2 and 6.1  0.8 for the vehicle- and 6-
hydroxynorketamine-treated groups, respectively (p = 0.22),
indicating no significant inhibition of morphine metabolism by
6-hydroxynorketamine. At 90 min. after administration, nota-
ble 6-hydroxynorketamine concentrations were observed both
in the brain and serum (fig. 4E) with a brain-to-serum ratio of
A B
C D
Fig. 2. Effects of ketamine or 6-hydroxynorketamine on acute morphine nociception and motor coordination. All rats received subcutaneous mor-
phine (Mo) 2.5 mg/kg at –15-min. time-point. At time-point 0, rats received subcutaneous (2S,6S;2R,6R)-hydroxynorketamine (6-hydroxynorketa-
mine) 30 mg/kg (6-Hnk 30) or 10 mg/kg (6-Hnk 10), ketamine 10 mg/kg (Ket 10) or vehicle. Nociceptive thresholds were monitored up to
90 min. after administration using the tail flick (TF, A), hot plate (HP, B) and paw pressure (PP, C) tests. The rotarod test (D) was used to screen
for motor coordination deficiencies. The mean (S.E.M.) of the maximum possible effect (MPE%) is plotted for the nociceptive tests, and for the
rotarod test, the mean (S.E.M.) percentage change from the baseline is shown. **p < 0.01, ***p < 0.001 as compared with the group that
received morphine with vehicle. n = 7 per group.
A B
C D
Fig. 1. Effects of acute ketamine or 6-hydroxynorketamine on nociception and motor coordination. Drug-na€ıve rats received subcutaneous
(2S,6S;2R,6R)-hydroxynorketamine (6-hydroxynorketamine) 30 mg/kg (6-Hnk 30) or 10 mg/kg (6-Hnk 10), ketamine 10 mg/kg (Ket 10) or vehi-
cle. Nociceptive thresholds were monitored up to 90 min. after administration using the tail flick (TF, A), hot plate (HP, B) and paw pressure (PP,
C) tests. The rotarod test (D) was used to screen for motor coordination deficiencies. The mean (S.E.M.) of the maximum possible effect
(MPE%) is plotted for the nociceptive tests, and for the rotarod test, the mean (S.E.M.) percentage change from the baseline is shown.
**p < 0.01, ***p < 0.001 as compared with the group that received vehicle. n = 7 per group.
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1.1. Pre-treatment with morphine pumps led to doubled 6-
hydroxynorketamine concentrations both in the brain and
serum. No significant amounts of ketamine or norketamine
were detected after the administration of 6-hydroxynorketa-
mine.
Co-administration of 6-hydroxynorketamine with chronic
morphine does not lead to reduced development of tolerance.
Rats were implanted with morphine pumps on day 0, and sub-
cutaneous vehicle or 6-hydroxynorketamine (20 mg/kg) was
administered twice daily. Nociceptive latencies were monitored
on days 2, 4 and 6 before the administration of 6-hydroxynor-
ketamine or vehicle. On day 2, morphine antinociception was
at its highest in the tail flick test (fig. 5A), whereas in the hot
plate (fig. 5B) and paw pressure (fig. 5C) tests, tolerance to
the effect of morphine had already developed. On day 2 in the
hot plate test, compared with vehicle, co-administration of 6-
hydroxynorketamine led to a significantly greater nociceptive
latency. However, this effect was not observed in the tail flick
or paw pressure tests. On day 6, after baseline measurements,
rats received a subcutaneous test dose of morphine (10 mg/kg)
without any acute 6-hydroxynorketamine. Morphine produced
A B C
Fig. 3. Tolerance development to the antinociceptive effect of morphine delivered by subcutaneous minipumps. On day 0, s.c. minipumps deliver-
ing morphine 9.6 mg/day were implanted under brief isoflurane anaesthesia. The means (S.E.M.) of the tail flick latencies (A), hot plate latencies
(B) and paw pressure thresholds (C) are shown 1 and 6 days after pump implantation. The mean raw latencies or thresholds are shown to allow
assessment of data quality. ***p < 0.001; significantly different between the indicated groups. n = 28.
A
C D E
B
Fig. 4. Effects of acute ketamine or 6-hydroxynorketamine on nociception in morphine-tolerant rats under chronic morphine treatment. On day 0,
rats were implanted with subcutaneous minipumps administering morphine 9.6 mg/day. On day 6, rats received subcutaneous (2S,6S;2R,6R)-hydro-
xynorketamine (6-hydroxynorketamine) 30 mg/kg (6-Hnk 30) or 10 mg/kg (6-Hnk 10), ketamine 10 mg/kg (Ket 10) or vehicle. Nociceptive thresh-
olds were monitored up to 90 min. after administration using the tail flick (TF, A), hot plate (HP, B) and paw pressure (PP, C) tests. The mean
(S.E.M.) of the maximum possible effect (MPE%) is plotted for the nociceptive tests. At 90 min., the mean serum and whole brain concentrations
of morphine (D) and 6-hydroxynorketamine (E) in selected groups were quantified using HPLC-MS. Mean concentrations (S.E.M.) are shown.
*p < 0.05, **p < 0.01, ***p < 0.001 as compared with the group that received morphine with vehicle. #p < 0.05, ###p < 0.001 between the indi-
cated groups. n = 7 per group.
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significant antinociception in all nociceptive tests 30 min.
after administration. Previous cotreatment with 6-hydroxynor-
ketamine did not significantly influence the acute effects of
the test dose, and also no differences in serum or brain con-
centrations of morphine (fig. 5D) or M3G (fig. 5E) were
found.
Discussion
The present study shows that acute administration of ketamine
significantly enhanced morphine antinociception, whereas its
secondary metabolite 6-hydroxynorketamine did not influence
nociceptive latencies alone or co-administered with morphine.
Developed morphine tolerance was also attenuated by keta-
mine but not 6-hydroxynorketamine. Co-administration of
6-hydroxynorketamine twice daily did not affect the develop-
ment of morphine tolerance. Acute 6-hydroxynorketamine did
not impair motor coordination, in agreement with previous
results [17].
Significant 6-hydroxynorketamine brain concentrations
(800 ng/g  3 lM) were detected 90 min. after the adminis-
tration of a 30 mg/kg dose, supporting previous findings
showing that 6-hydroxynorketamine readily passes to the cen-
tral nervous system [12,29]. This exceeds the EC50 for nega-
tive allosteric modulation of a7-nACh receptors (100 nM)
[30]. In the present and also in our previous study, ketamine
(10 mg/kg s.c.) administration significantly attenuated mor-
phine tolerance at 30 and 90 min. At these time-points, 6-
hydroxynorketamine brain concentrations were 770  370 and
660  300 ng/g, respectively (mean  S.D., n = 4, unpub-
lished findings). As the 6-hydroxynorketamine brain concen-
trations were at the same level after ketamine or direct 6-
hydroxynorketamine administration in those studies, we can
conclude that 6-hydroxynorketamine does not contribute to the
effects of ketamine on morphine tolerance.
Effects of 6-hydroxynorketamine on nociception have not
been previously studied. The original work studying the
anaesthetic properties of ketamine, norketamine and
6-hydroxynorketamine [12] found no anaesthetic effects by
6-hydroxynorketamine. Later studies confirmed that 6-hydro-
xynorketamine is not an NMDA receptor antagonist [30].
However, 6-hydroxynorketamine is a negative allosteric modu-
lator of a7-nACh receptors already at 100 nM [30], a concen-
tration much lower than the one achieved in this study after
the 30 mg/kg dose (3 lM). Negative allosteric modulation of
a7-nACh receptors proposedly leads to multiple effects that
may have opposite actions regarding nociception and opioid
tolerance. Firstly, inhibition of a7-nAch receptor function and
decreased cellular Ca2+ influx in nociceptors may lead to
decrease in nociceptive glutamatergic signalling. Secondly,
activation of the downstream mechanistic target of rapamycin
(mTOR) pathway [31] by 6-hydroxynorketamine may lead to
A
C D E
B
Fig. 5. Effects of 6-hydroxynorketamine cotreatment on developing morphine tolerance. On day 0, rats were implanted with subcutaneous mor-
phine (Mo) pumps delivering 9.6 mg/day morphine. During days 0–5, rats received subcutaneous (2S,6S;2R,6R)-hydroxynorketamine (6-hydroxy-
norketamine) 20 mg/kg (6-Hnk 20) or vehicle (Veh) twice daily (bid). The last injection was given on day 5 evening. The development of
antinociceptive tolerance to morphine was assessed on days 2, 4 and 6 using tail flick (TF, A), hot plate (HP, B) and paw pressure (PP, C) tests.
In the morning of day 6, after assessment of the baseline nociceptive values, both groups received an acute subcutaneous dose of morphine
(10 mg/kg) and nociceptive tests were used 30 and 90 min. after administration. The mean (S.E.M.) of the maximum possible effect (MPE%) is
plotted for the nociceptive tests. Directly after the 90-min. measurements, serum and whole brain samples were collected and the mean (S.E.M.)
morphine (D) and morphine-3-glucuronide (M3G, E) concentrations were quantified using HPLC-MS. *p < 0.05 as compared with the group that
received morphine pumps and vehicle. n = 6–7 per group.
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decreased production of D-serine [31–33], an important
NMDA receptor co-agonist. Decreased D-serine levels have
previously been associated with attenuation of morphine toler-
ance [34,35]. However, in other studies, activation of the
mTOR pathway has been linked to the development of opioid
tolerance and hyperalgesia [36,37]. Interestingly, a7-nACh
receptor agonists have shown efficacy in pre-clinical models
of neuropathic pain [38,39] and remifentanil-induced hyperal-
gesia [40] by reducing the release of glial pro-inflammatory
cytokines. Finally, recent studies exploring the mechanisms of
6-hydroxynorketamine-induced antidepressive actions show
that 6-hydroxynorketamine may indirectly increase excita-
tory a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptor glutamatergic signalling [17,41]. Based on
these observations, it is difficult to predict the net effect of
a7-nACh receptor antagonists such as 6-hydroxynorketamine
on opioid antinociception. In the present study, administration
of 30 mg/kg 6-hydroxynorketamine resulted in significant
brain concentrations but did not produce either antinociception
or pronociception alone or combined with morphine in acute
thermal and mechanical tests of nociception. Moreover, 6-
hydroxynorketamine did not attenuate developed opioid toler-
ance in a similar manner as acute ketamine did. Also, the
chronic twice-daily administration of 6-hydroxynorketamine
did not affect the development of tolerance.
In the tolerance experiment of the present study, acutely
administered 6-hydroxynorketamine increased the brain mor-
phine concentration by 60% with small (non-significant)
additive effects (15 MPE%) in the nociceptive tests com-
pared with the group that received vehicle. It is likely that in
well-developed morphine tolerance, a 60% increase in the
brain morphine concentration is not sufficient to cause signif-
icant attenuation of tolerance. In our previous studies using a
similar model of morphine tolerance, acute ketamine (10 mg/
kg) [21] and norketamine (30 mg/kg) [16] administered to
rats under chronic morphine treatment increased brain and
serum morphine concentrations much more, three- to fivefold
90 min. after acute administration. Previous in vitro studies
show that ketamine inhibits UGT2B7 [22,23], an enzyme
that metabolises morphine to its glucuronides [42]. In rats,
morphine is glucuronidated to M3G by the orthologue
Ugt2b1 [43–45]. In our study, the increase in morphine con-
centrations was associated with a decrease in the serum and
liver M3G-to-morphine metabolic ratio [21], indicating the
inhibition of morphine metabolism by ketamine and norke-
tamine. So far, no data about the inhibitory properties of
UGT2B7 and/or Ugt2b1 by hydroxynorketamines exist. The
present results suggest that in the rat, 6-hydroxynorketamine
is a much weaker inhibitor of the Ugt2b1 enzyme than
ketamine.
Chronic administration of morphine led to doubled 6-hydro-
xynorketamine concentrations in the brain 90 min. after acute
administration, which is an important observation for future
drug development. A similar interaction was also found when
ketamine [21] and norketamine [16] were administered to mor-
phine-treated rats. The mechanism behind this interaction
needs further study.
In conclusion, this study strengthens the pre-clinical evi-
dence that ketamine efficiently augments morphine antinoci-
ception and reverses morphine tolerance. The secondary
metabolite of ketamine, (2S,6S;2R,6R)-hydroxynorketamine,
did not show antinociceptive effects in thermal or mechanical
models of nociception when administered either alone or with
acute or chronic morphine. It also did not affect motor coordi-
nation of rats. Acute 6-hydroxynorketamine only slightly
increased the brain concentrations of morphine, suggesting that
it is not a strong inhibitor of morphine glucuronidation. The
effects of ketamine metabolites should be studied also in mod-
els of neuropathic pain to better understand the mechanisms of
ketamine and its metabolites in the treatment of pain.
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